Association of International Pharmaceutical Manufacturers Admits New Members

December 26, 2022, Moscow. - Association of International Pharmaceutical Manufacturers (AIPM) announces the expansion of the membership. Following the AIPM General Meeting, LLC “Ipsen Consumer Healthcare” and the manufacturer of active pharmaceutical ingredients EUROAPI were admitted to the Association.

LLC “Ipsen Consumer Healthcare” is represented on the Russian market in the segment of the over-the-counter medicines. The current portfolio of the company was established via the acquisition of Ipsen Consumer Healthcare division by Mayoly Spindler in July, 2022.

“The main goal of the company is to provide healthcare professionals and patients with innovative therapeutic solutions to improve the quality of life and health of patients every day. Being in line with our mission we share the fundamental principles and values of the Association and its members. We are confident in the importance of being part of a leading industry association that has repeatedly proven its highest level of expertise and commitment to finding optimal decisions for the benefit of patients and the development of the pharmaceutical market. We are confident that we will be able to contribute to the work of the Association," said General Director Alla Bogdanova.

EUROAPI is the new European player focused on the development and production of small molecule active pharmaceutical ingredients (API). The company offers of approximately 200 API in its portfolio, as well as its own R&D capabilities for the development in more complex molecules segments through Contract Development and Manufacturing Organization (CDMO). EUROAPI was established in 2021 setting apart from Sanofi as independent company.

Welcoming the General Meeting decision on the new applications, AIPM Executive Director Vladimir Shipkov stressed: "The Association, being the largest industry professional union of the pharmaceutical manufacturers, consistently fulfills its mission to ensure the availability of high-quality, effective and safe medicines for patients in our country. It is noteworthy that we consolidate in our ranks the wide range of companies that produce original, orphan, and generic medicines, both prescription and over-the-counter, and now also active pharmaceutical ingredients. Such a multidisciplinary approach requires the highest level of professional excellence and expertise, the ability to deliver the well-balanced solutions to acute industry challenges in the spirit of social responsibility and strong partnership. We continue to focus on finding solutions aimed primarily at the benefit of the patients, while being based on the values of constructive dialogue with all pharmaceutical market interested participants.”

_______________

Reference:

Association of International Pharmaceutical Manufacturers (AIPM) was established in 1994 and represents in the Russian Federation the leading international pharmaceutical companies - producers and developers of modern effective, safe and high-quality medicines. Today, AIPM unites more than 60 international companies that provide over 80% of the world’s pharmaceutical products and over 60% of medicines imported to the Russian Federation.

For additional information, please, contact:

Elena Yankovskaya, PR & Communications Director, AIPM

Elena.Yankovskaya@aipm.org

About LLC “Ipsen Consumer Healthcare”:

LLC “Ipsen Consumer Healthcare” is part of the Mayoly Group. The headquarters is in Paris (France). The company focuses on consumer healthcare business. The division's portfolio includes 8 medicines and a biologically active additive. The products are presented in more than 80 countries. The company's website is under development, soon information about the drugs will appear on the website: https://mayoly-spindler.ru

For additional information, please, contact:

Darya Pokrashinskaya, Communications Specialist, LLC “Ipsen Consumer Healthcare”

Darya.Pokrashinskaya.ext@s.mayoly.com

About EUROAPI:

EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies, while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities. Taking action for health by enabling access to essential therapies inspires our 3,350 people every day. With strong research and development capabilities and six manufacturing sites all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.

Find out more at www.euroapi.com